Chronic Myelogenous Leukemia News and Research

Latest Chronic Myelogenous Leukemia News and Research

Study shows long-term benefits for chronic myeloid leukemia patients receiving therapy with imatinib

CHU in Poitiers, France, yesterday announced results of a study showing that newly diagnosed patients with a certain form of leukemia who are treated early with imatinib are more likely to achieve complete cytogenetic responses (the elimination of leukemic cells, a major goal of therapy) and have improved long-term outcomes.

6 Dec 2004

New drug can successfully treat patients who have become resistant to Gleevec

A team of prominent researchers led by Charles Sawyers, M.D. and Moshe Talpaz, M.D., presented compelling clinical findings today showing that a new drug, BMS-354825, can successfully treat patients who have become resistant to Gleevec (the frontline therapy for chronic myelogenous leukemia, CML).

5 Dec 2004

A new treatment for patients with chronic myeloid leukemia

A new treatment for patients with chronic myeloid leukemia (CML) -- a disorder marked by an overproduction of white blood cells -- yields positive results in those who have relapsed on imatinib, the standard treatment for the disease, according to a Phase I study to be presented today at the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Imatinib mesylate (Gleevec) inhibits important pathways that spur cancer growth

A new clinical study has shown that imatinib mesylate (Gleevec) has activity in AIDS-related Kaposi's sarcoma (KS). Imatinib inhibits important pathways that spur cancer growth, resulting in the regression of KS tumors within 4 weeks in some patients. The study will be published November 30 in the Journal of Clinical Oncology (JCO).

30 Nov 2004

Impaired cognitive and motor function following stem cell transplantation for severe blood disorders can improve

Patients who suffer a loss of cognitive and motor function as a result of stem cell transplantation for severe blood disorders are likely to see those functions return to previous levels after one year, according to a new study in the November 15, 2004, issue of Blood, the official journal of the American Society of Hematology.

8 Nov 2004

Researchers have documented a novel form of resistance in leukemia cells to an anti-cancer drug

Researchers at Virginia Commonwealth University’s Massey Cancer Center have documented a novel form of resistance in leukemia cells to an anti-cancer drug, which could help scientists develop new strategies for treating the disease.

8 Nov 2004

Obesity could more than double an older woman's risk of acute myelogenous leukemia

A study from the University of Minnesota Cancer Center indicates that overweight and obesity could more than double an older woman's risk of acute myelogenous leukemia (AML), an often fatal cancer of the bone marrow and blood.

8 Nov 2004

Gene silencing may provide hope for leukemia sufferers

Ever since the approval of Gleevec in 2001, a cancer-cell-specific drug used to treat chronic myelogenous leukemia (CML), the field of cancer therapeutics has been rushing full speed into the era of so-called "targeted" medicines.

1 Nov 2004

Experimental drug PKC412 may be the key to treating myeloproliferative disease

Scientists at Dana-Farber Cancer Institute and Brigham and Women's Hospital have prolonged the lives of mice with a rare blood disorder by using an experimental drug that blocks signals promoting runaway growth of blood cells.

21 Sep 2004

Stanford researchers identify leukemia stem cells

A handful of leukemia cells constantly replenish the supply of cancerous cells, according to new work by Stanford University School of Medicine researchers.

11 Aug 2004

New compound that is designed to overcome Gleevec resistance

One of the truly spectacular success stories in modern oncology is the development and implementation of Gleevec, a drug that virtually halts the progress of chronic myeloid leukemia. Yet for some patients who harbor particularly stubborn genetic mutations, Gleevec fails miserably.

17 Jul 2004

New whole body positron emission tomography (PET) imaging allows scientists to watch as immune system respond to tumors or infection

Compared to the snapshot views of the immune system from tumor biopsies or blood assays, this whole body imaging allows scientists to track how the immune response changes, and the tumor or infection responds, throughout the different phases of immune response and over long periods of time.

15 Jun 2004

SU11248 proves effective in the treatment of gastrointestinal stromal tumors

A drug originally developed to block the formation of blood vessels in tumors has been shown to overcome resistance to treatment with Gleevec in patients with gastrointestinal stromal tumors (GIST).

9 Jun 2004

Umbilical cord blood and bone marrow transplants slow the progression of many cancers

Umbilical cord blood and bone marrow transplants at Loyola University Health System, Maywood, Ill., are curing or slowing the progression of many cancers originating in the bone marrow (i.e., leukemia, myeloma) or lymphatic system (lymphoma).

3 Jun 2004

Developing smart drugs

Dana-Farber Cancer Institute Researchers, sensing an opening in the cancer battle, are mounting a quick thrust to flush out suspected molecular cancer triggers in tumor cells.

30 Apr 2004

AGT Biosciences Limited and ChemGenex Therapeutics today announced merger agreement

AGT Biosciences Limited of Melbourne, Australia and privately held ChemGenex Therapeutics, Inc. of Menlo Park, California, today announced that they have signed a merger agreement. The cross-border merger creates a new, genomics-driven pharmaceutical company with leading edge capabilities for drug discovery and development, as well as two drug candidates in Phase II human trials for cancer.

28 Apr 2004

St. John’s wort may interfere with cancer-fighting drug’s ability to prevent relapse in leukemia patients

St. John’s wort, an herb thought to be a safe, natural remedy for mild depression, may interfere with a powerful cancer-fighting drug’s ability to prevent relapse in leukemia patients, a University of Florida pharmacy researcher will report March 27 at the annual meeting of the American Society for Clinical Pharmacology and Therapeutics.

26 Mar 2004

Chronic Myelogenous Leukemia News and Research

Latest Chronic Myelogenous Leukemia News and Research

Study shows long-term benefits for chronic myeloid leukemia patients receiving therapy with imatinib

New drug can successfully treat patients who have become resistant to Gleevec

A new treatment for patients with chronic myeloid leukemia

Imatinib mesylate (Gleevec) inhibits important pathways that spur cancer growth

Impaired cognitive and motor function following stem cell transplantation for severe blood disorders can improve

Researchers have documented a novel form of resistance in leukemia cells to an anti-cancer drug

Obesity could more than double an older woman's risk of acute myelogenous leukemia

Gene silencing may provide hope for leukemia sufferers

Experimental drug PKC412 may be the key to treating myeloproliferative disease

Stanford researchers identify leukemia stem cells

New compound that is designed to overcome Gleevec resistance

New whole body positron emission tomography (PET) imaging allows scientists to watch as immune system respond to tumors or infection

SU11248 proves effective in the treatment of gastrointestinal stromal tumors

Umbilical cord blood and bone marrow transplants slow the progression of many cancers

Developing smart drugs

AGT Biosciences Limited and ChemGenex Therapeutics today announced merger agreement

St. John’s wort may interfere with cancer-fighting drug’s ability to prevent relapse in leukemia patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Chronic Myelogenous Leukemia News and Research

Latest Chronic Myelogenous Leukemia News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in